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Ankle-brachial index with Doppler ultrasound, despite limitations in diabetic and endstage renal failure patients, is the first-line evaluation of CLI. In this group of patients, toe-brachial index measurement may better establish the diagnosis. Other non-invasive measurements, such as segmental limb pressure, continuous-wave Doppler analysis and pulse volume recording, are of limited accuracy. Transcutaneous oxygen pressure (TcPO 2 ) measurement may be of value when rest pain and ulcerations of the foot are present. Duplex ultrasound is the most important non-invasive tool in CLI patients combining haemodynamic evaluation with imaging modality.
Computed tomography angiography (CTA) and magnetic resonance angiography (MRA) are the next imaging studies in the algorithm for CLI. Both CTA and MRA have been proven effective in aiding the decision-making of clinicians and accurate planning of intervention. The data acquired with CTA and MRA can be manipulated in a multiplanar and 3D fashion and can offer exquisite detail. CTA results are generally equivalent to MRA, and both compare favourably with contrast angiography. The individual use of different imaging modalities
Non-invasive vascular laboratory tests
In patients with critical limb ischaemia (CLI) an accurate diagnosis can be established with modern non-invasive vascular diagnostic techniques to provide adequate information for creation of a therapeutic plan. When required, non-invasive physiological and anatomical data will be supplemented by the use of more accurate imaging techniques, such as computed tomography angiography (CTA) or magnetic resonance angiography (MRA), and selective use of lower extremity angiographic techniques.
The objectives of modern non-invasive testing of patients with peripheral arterial disease are:
• to confirm the presence of the disease • to provide reproducible physiological data concerning disease severity • to document the location and haemodynamic importance of vascular lesions • to make a detailed plan in case intervention is needed.
These tests can be repeated over time to follow disease progression and results of treatment.
Non-invasive assessment of patients with CLI can be broadly grouped into three general categories of techniques:
• physiologic or haemodynamic measurements • measurements of tissue perfusion • anatomic imaging.
Each modality has advantages, disadvantages and limitations.
Non-invasive techniques assessing physiological parameters of pressure and flow can provide an initial assessment of the location and severity of arterial disease. Doppler ultrasonography and plethysmography, each with various forms and techniques, are the two most commonly used haemodynamic methods to evaluate patients with CLI.
Measurements of tissue perfusion include microcirculation techniques; the most commonly employed is transcutaneous partial pressure of oxygen (TcPO 2 ) measurements.
Non-invasive anatomic imaging is usually based on a combination of Doppler haemodynamic and B-mode ultrasonography imaging and will be detailed in the second part of this chapter ("Imaging techniques. Duplex ultrasound").
Physiological and haemodynamic
measurements (Table 1) 
Doppler ultrasonography
Doppler ultrasonography is the single most important modality in non-invasive evaluation of vascular disease extent. Ultrasound techniques are based on the principle that sound waves emitted from a probe are reflected at the interface of two surfaces; the observation that an ultrasound wave undergoes a frequency shift proportional to the velocity of any moving object encountered (e.g. red blood cells) is known as Doppler principle. Both quantitative and qualitative measurements of flow are allowed by Doppler ultrasonography. Quantitative analyses are based on pressure measurements and include ankle-brachial and toe-brachial indices and segmental pressure; qualitative measurements are based on the analysis of the shape and morphology of Doppler waveforms.
Ankle-brachial index (ABI)
The single most valuable and commonly used diagnostic test in the evaluation of peripheral arterial occlusive disease is measurement of the ankle-to-brachial systolic blood pressure ratio, termed ankle-brachial index (ABI). The ABI is a simple, inexpensive, non-invasive test that can be performed easily in most clinical settings; it is measured with a handheld continuous-wave Doppler ultrasound probe and a blood pressure cuff: the highest systolic pressure measured from either the posterior tibial or dorsalis pedis artery (in each leg) is divided by the highest brachial artery pressure taken from either arm. Optimal recordings are obtained with blood pressure cuffs that are appropriately sized to the patient's lower calf, immediately above the ankle. Systolic pressures are recorded with a Doppler probe after the patient has been at rest in supine position for 5 minutes. Pulse wave reflection in healthy individuals causes the ankle pressure to be 10--15 mmHg higher than the brachial artery systolic pressure. 2--4 If the arm blood pressures are not equal, a subclavian/axillary stenosis or occlusion might be present, and the arm with the highest blood pressure is used for subsequent blood pressure ratio calculations. In patients with ischaemic ulcers, the ankle pressure is typically 50--70 mmHg, and in patients with ischaemic rest pain it is typically 30--50 mmHg. However, falsely high values can be recorded in CLI patients, in whom the ABI test is not reliable due to incompressible calcified vessels as in patients with long-standing diabetes, advanced age or end-stage renal disease.
The ABI provides objective data that serve as the firstline assessment for the diagnosis of lower limb vascular disease and has been used either as a baseline diagnostic tool for patients with CLI (foot ulcer or rest pain) or to monitor the efficacy of therapeutic interventions. The normal range of ABI is quoted as 0.91--1.31. 4, 5 The cutoff point for diagnosis of vascular disease is typically set at 0.90 at rest. 1 ABI values between 0.41 and 0.90 are considered "mildly to moderately" diminished and an ABI of 0.40 or less as "severely" decreased. Although it has been suggested that patients with an ABI <0.40 are more likely to develop ischaemic rest pain, ischaemic ulceration, or gangrene, compared to patients with an ABI 0.5, there is no general consensus regarding the prognostic value of these ABI categories for peripheral disease. 1,2,6--11 In diabetic patients, Clairotte et al. reported that the cut-off values for the highest sensitivity and specificity for vascular disease screening were between 1.0 and 1.1.
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ABI measurement is claimed to be a simple and reproducible test. Reporting standards require a change of 0.15 to be considered clinically relevant, or >0.10 if associated with a change in clinical status. Well-controlled, repeated measurements are accurate enough to be used as a clinical indicator in decision-making. However the reproducibility may vary among experienced physicians. 5, 7, 8, 12, 13 It has been shown that the reproducibility of ABI assessment by pocket Doppler may be dependent on the level of experience of the operator. 6,14--17 Inter-observer variability among experienced physicians has a reported k-statistic of 0.77 to 1.0. Intra-observer variability ranges from 7.3% to 12%. 5, 7, 8, 12, 13 Holland-Letz and Endres and colleagues 18, 19 found small intra-(8%) and inter-observer errors (0--9%) among different practitioner groups in large unselected populations.
Different modes of determination and calculation of the ABI can be applied especially in primary care practices. 6 Klein and Hage found 39 different ways to calculate the ABI. 20 Nicolai et al., investigating the use of ABI in nonspecialist settings, showed that eight different methods were commonly used for calculation of the ABI in primary care practices. 6 A recently published literature analysis that evaluated the methodology of ABI determination in 100 random publications demonstrated great variability with respect to the methods of ankle and brachial blood pressure measurements as well as calculation of the index. 21 Major international societies 2, 4 recommend calculating the ABI by dividing the highest pressure in the leg by the highest pressure in the arm to guarantee good reproducibility. Use of a standardised step-by-step technique for measuring ABI is required for reproducibility of measurements.
ABI has been largely validated against contrast-enhanced angiography to determine obstructions greater than 50%. The ABI has been reported to be 95% sensitive and 99% specific for peripheral disease detection when a 0.9 cut-off level from measurements is used. 22--25 In general, the sensitivity of ABI ranges from 80% to 95% and the specificity from 95% to 100%, with positive and negative predictive values in excess of 90%. 1, 5, 6, 22 However, as pointed out by AlQaisi et al. in a recent update on ankle-brachial index (2009 review), the majority of authors quoting detection accuracy for ABI normal/abnormal ranges refer back to original data from pioneering works performed in the 1970s and 1980s. 5,26--31 The diagnostic accuracy of ABI as a screening test may be limited in diabetic patients, especially those with nephropathy, foot lesions and old age, probably due to the high prevalence of medial arterial calcifications causing a high prevalence of false negative values. Sensitivity ranging from 63% to 100% and specificity values of 85--97% have been reported in these patients. 7,32--36 In a recent study analysing patients undergoing both ABI and angiography measurements, Chung et al. showed that the most significant factor affecting the validity of ABI was diabetes (OR 4.36 for false-negative results). 37 Although CLI is very common in diabetic patients (prevalence of vascular disease estimated around 13.6% vs. 4% in the general population), 7, 38 it often remains under-recognised in this population. 7, 39 Diagnosis is often difficult because the co-existence of peripheral neuropathy could mask the ischaemic pain. In these settings sensitivity in detecting vascular disease of ABI ranges from 50% to 71% and specificity from 30% to 96.8%. 7,11,34,40--42 The ABI is relatively insensitive for determining progression of lower limb occlusive disease when compared to arteriography or duplex ultrasonography. McLafferty et al. found an ABI sensitivity of 41%, specificity of 84%, positive predictive value of 59% and overall accuracy of 68% in detecting disease progression. 43 In addition to its use in evaluating symptomatic patients affected by peripheral vascular disease, decreased ABI is a strong predictor of cardiovascular events and premature mortality. 44--47 An ABI <0.90 is associated with a 3-to 6-fold increased risk of cardiovascular mortality. 45--48 A metaanalysis in 2008 by Fowkes et al. 49 found that abnormal ABI was associated with approximately twice the 10-year total mortality, cardiovascular mortality, and major coronary event rate compared with the overall rate in each Framingham risk score category. The American Diabetes Association recommends screening for ABI in all diabetic patients aged >50 years, as well as in younger insulin-dependent patients with other vascular risk factors. 35, 45, 47, 50, 51 ABI measurement can be used as a prognostic index to facilitate initiation of treatment (hypertension, dyslipidaemia, diabetes, etc.) to reduce cardiovascular events and should be routinely performed in patients aged 70 years, with rest pain or ulcers, and those with a history of diabetes or smoking. 47 Although the ABI has gained widespread acceptance as a single, accurate and reproducible first-line method to evaluate arterial occlusive disease and a valid cardiovascular prognostic instrument, the test has definite limitations and it should be associated with duplex ultrasound imaging.
Summary messages (advantages and limitations of ABI):
• ABI can be useful as a routine measurement in primary care practices providing objective and reproducible firstline assessment of CLI. It is sensitive and specific in the differential diagnosis of leg symptoms to identify or rule out a vascular aetiology.
• ABI measurement is a widely applicable, simple, quick, cost-effective and non-invasive tool to establish or disprove the baseline for CLI and to follow revascularisation results.
• ABI can provide objective data that serve as the standard in office practice, vascular laboratories and epidemiological surveys.
• ABI provides indirect information on arterial disease but cannot localise the anatomical level of a pressure-reducing obstruction.
• The reproducibility of ABI measurements is dependent on the level of experience of the operator and may vary among experienced physicians, university hospitals and in community settings.
• ABI may not be accurate in the presence of incompressible lower extremity arteries as occurs in very elderly individuals, diabetics, or patients with long-standing renal disease.
• Use of a standardised step-by-step technique for measuring ABI is required to ensure reproducibility of measurements.
Recommendations
The resting ABI is useful in the initial evaluation for CLI and can be easily and quickly measured on both legs to confirm diagnosis and establish the severity of disease in patients with rest leg/foot symptoms as well as individuals with foot non-healing ulcer and lower limb rest pain.
(Level 2b; Grade B)
The resting ABI in all new patients with CLI can be used to establish the baseline to evaluate the effect after revascularisation procedures. 52, 53 Absolute toe pressures <30 mmHg are required to diagnose CLI in patients with rest pain. 2 For patients with ulcers or gangrene, the presence of CLI is diagnosed by toe systolic pressure <50 mmHg. Absolute toe pressure of 55 mmHg or greater has been correlated to be predictive for foot ulcer healing in diabetic patients, and TASC requires toe pressure <50 mmHg (critical level) to confirm CLI diagnosis in diabetic patients. 2 Toe pressure measurements were shown to be more reliable than ABI measurements in patients with diabetes associated with falsely high ABI values and peripheral neuropathy. 34, 54, 55 Brooks et al. compared TBI and ABI in 174 diabetics and 53 controls and found comparable indices when ABI was low or normal (84% and 78% agreement, respectively), but not when ABI was elevated. 54 In the presence of clinical peripheral neuropathy, toe pressure sensitivity has been evaluated to be 100% and ABI sensitivity 53%. 34 However, TBI measurement requires appropriate technique and tools (small cuffs), therefore it is not widely applicable and the overall accuracy may be limited. Furthermore, it may be impossible to measure toe pressures in patients with inflammatory lesions, ulceration or loss of tissue.
Summary messages (advantages and limitations of toebrachial index):
• Toe-brachial index is a quick way to non-invasively establish or disprove the CLI diagnosis in patients with lower limb rest pain or non-healing ulcers.
• Toe-brachial measurements are particularly useful in individuals with incompressible crural and pedal arteries.
• The test requires small cuffs and a careful technique to preserve accuracy.
Recommendation
Toe-brachial index is useful to establish CLI diagnosis in patients in whom CLI is clinically suspected (non-healing ulcer, rest pain) but the ABI test is not reliable due to incompressible vessels as in patients with diabetes, advanced age or long-standing renal failure. (Level 2b; Grade B)
Segmental limb pressure
The location and extent of CLI can be indirectly defined in a non-invasive laboratory by segmental limb systolic pressure measurements, recorded with a Doppler instrument and blood pressure cuffs placed over the brachial arteries and sequentially at various points on the lower limbs, including the upper and lower thigh, the upper calf, the ankle, and metatarsal. Theoretically, the cuff width should be 20% greater than the diameter of the limb at the point where it is applied. Narrow cuffs may be associated with the appearance of falsely high pressures and do not permit accurate disease localisation. 1,2 The examination is performed by placing a Doppler probe over the most prominent arterial signal at the ankle with the patient in supine position. In most laboratories a 20 mmHg gradient between adjacent segment cuffs is regarded as indicative of a significant occlusive lesion. Thus, by comparing the pressures obtained at different levels, segmental pressure measurement can detect the location of arterial occlusive lesions with reasonable accuracy. Segmental pressure measurements can provide information in patients with multi-level disease and predict ulcer healing, limb survival or the need for further additional revascularisation. 54--56 However, as already stated by the TASC II and AHA Guidelines, 1, 2 there are a number of limitations and potential problems in the analysis of segmental limb pressure that render it an old-fashioned diagnostic technique for CLI evaluation.
• Isolated moderate stenosis (usually iliac) that produces little pressure gradient may be missed.
• Calcified arteries may lead to falsely elevated ankle pressures.
• In patients with multi-level disease, decreased proximal pressures may mask more distal gradients.
• Segmental pressure gradients are not suitable to differentiate between short-and long-segment lesions or between highly stenotic arteries and occlusions.
• Reduced thigh pressure is usually indicative of a pressurereducing obstruction along the aorto-iliac axis; however, similar findings may be produced by an obstruction of the common femoral or proximal superficial femoral and deep femoral arteries.
• Artefacts on measurements due to inappropriate cuff size/position are common. 
Continuous-wave Doppler ultrasound
Quantitative and qualitative analysis performed by continuous-wave Doppler ultrasound remains an old-fashioned technique which is no longer routinely used in many modern diagnostic vascular laboratories. The AHA guidelines recognise that Doppler waveforms analysis needs to be combined with ultrasound visualisation of arterial vessel ("duplex imaging") to maximise the benefits of this technique. 1 Analysis of morphology of the continuous-wave Doppler waveform was suggested to provide useful information in localising and quantifying vascular disease in patients with poorly compressible arteries. Many patients with diabetes or end-stage renal disease, without palpable pulses and monophasic Doppler signals, may have an ABI greater than 1.0, which is a deceptive and misleading quantitative assessment of the severity of vascular disease. 57 The most commonly used "pulsatility index" is defined as the peak systolic velocity (or "frequency shift") divided by the mean blood flow velocity. Normally, the pulsatility index increases from the most proximal to the most distal segments of the lower extremities; a decrease between adjacent segments implies the presence of occlusive disease between these two locations. 57, 58 However, reversion to a normal waveform below a proximal stenosis may often occur. This phenomenon of "pulse normalisation" distal to some arterial stenosis is a recognised major diagnostic limitation of the technique that may occur especially in the presence of multi-level disease with high-resistance flow.
Furthermore, quantitative assessment of the pulsatility index is weakened in the presence of arterial calcifications.
Currently, the benefits of continuous Doppler waveform analysis are limited, and it should always be combined with ultrasound greyscale or colour visualisation of the arterial wall. Such "duplex imaging" represents one of the most widely used non-invasive vascular laboratory techniques replacing the traditional continuous-wave Doppler velocity analysis. 
Plethysmography
Plethysmography in CLI evaluation has been introduced in the past to detect changes in limb volume by "pulse volume recording" (PVR) which produces recordings that are similar to continuous Doppler waveforms. 59, 60 However, the lack of reliable, reproducible quantitative data limits the utility of plethysmography for diagnosis or arterial disease and CLI in most modern vascular laboratories today. With more widespread utilisation of ultrasound methods, the use of plethysmography has declined substantially.
The main value of PVR waveform analysis may be that it is not affected by medial calcification and therefore it is relatively useful in the diabetic population. 61 Accuracy of PVR and photoplethysmography has been tested against Doppler ultrasound in several studies, 56, 62, 63 indicating that the techniques might be useful in diabetic patients with CLI, including those with oedema, but the method may have poor accuracy in vascular diseases located in distal limb segments. 64 PVR tracings at the foot level have been used as an indicator of healing potential for foot wound or amputation procedures. 8, 45, 56, 65, 66 Limitations of PVR include that it may be a rather subjective tool for evaluation of CLI since measurements are based on subjective waveform analysis. PVR may be abnormal in patients with low cardiac stroke volume and overall accuracy is limited. Although quantitative criteria have been proposed in PVR, they are not widely used clinically owing to limited accuracy. 
Measurements of tissue perfusion
Different non-invasive measurements of tissue perfusion have been used to assess the severity of lower limb ischaemia. The applicability and reliability are generally limited with respect to Doppler ultrasonography.
Measurements of transcutaneous oxygen pressure (TcPO 2 ) reflect the metabolic state of lower limbs with CLI and diabetic feet. Small electrodes consisting of a circular silver--silver chloride anode surrounding a central platinum cathode are placed on the skin; oxygen diffusing to the surface of the skin is reduced at the cathode to produce a current proportional to the partial pressure of oxygen (PO 2 ) within the sensor. In patients with foot ulcers, tissue loss or rest pain, TcPO 2 values can be used to assess the presence and severity of vascular disease, the need for revascularisation, and to predict the success of healing with or without revascularisation. This test is performed by placing probes with electrodes on the foot and the leg, using the chest as a reference site. Common locations for assessment are the dorsum of the foot, the anteromedial aspect of the calf 10 cm below the knee, and the thigh 10 cm above the knee. Normal TcPO 2 values depend on age (higher for younger) and position (higher for proximal). Normal TcPO 2 levels are approximately 60 mmHg, while levels of 20 mmHg or less strongly suggest that revascularisation will be required to achieve healing. TASC II requires a critical level of TcPO 2 <30 mmHg to confirm diagnosis of CLI in patients with non-healing foot ulcers or diabetic foot. 2 Measurement of TcPO 2 is most helpful for evaluating cases of severe limb ischaemia, while it is relatively insensitive to mild or moderate degrees of peripheral vascular disease because the oxygen supply to the skin is far greater than the demand. TcPO 2 measurements combined with clinical determination may be of value to predict healing at various levels of amputation, especially in diabetic patients, because it is not affected by arterial calcification. 67--69 Nevertheless, measurements of TcPO 2 must be interpreted cautiously, since the test is often unreliable because it is affected by many factors that are difficult to control, including skin temperature, sympathetic tone, cellulitis, hyperkeratosis, obesity, oedema, metabolic activity, oxygen diffusion through tissue, age, vertical position of the site of measurements. In addition, when values are low, TcPO 2 is not linearly related to flow: a value of zero does not mean that there is no flow to the area of interest; rather it indicates that all the available oxygen has been consumed. Therefore, TcPO 2 is not routinely used in most vascular laboratories.
Measurement of skin perfusion pressure (SPP) is another microcirculatory assessment tool that can be utilised to assess foot healing potential. 70 Laser Doppler is not widely used in vascular laboratories, mainly because of an inability to calibrate the instrument to actual levels of blood flow and the availability of more accurate, direct methods for assessing CLI.
Hyperspectral tissue oxygenation measurements have also been used to predict healing of diabetic foot ulcers. The test should identify microvascular abnormalities in the diabetic foot, but this technology is currently being utilised mainly as a research tool. 71 Summary messages (advantages and limitations of tissue perfusion measurements):
• Tissue perfusion measurement can be useful to assess the severity of lower limb ischaemia.
• These techniques can be used in monitoring and/or reevaluating patients following endovascular or surgical revascularisation.
• Microcirculatory assessment of perfusion can be utilised to assess wound healing potential.
• Transcutaneous oxygen pressure (TcPO 2 ) is valuable to examine the metabolic state of the target tissue.
• Measurements of 
Duplex ultrasound
Duplex ultrasound (DUS) enables identification of the anatomical location and the degree of stenosis in lower extremity peripheral arterial disease (PAD) by combining both B-mode ultrasound and colour Doppler ultrasound. Haemodynamic assessment is performed by measuring peak systolic velocity (PSV) and PSV ratios within or beyond an obstruction compared with the adjacent upstream segment, the presence or absence of turbulence, and preservation of pulsatility. A PSV ratio of greater than 2:1 is considered to indicate a >50% stenosis, a PSV ratio greater than 4:1 a >75% stenosis and a PSV ratio of greater than 7:1 a >90% stenosis. 74 
Accuracy of DUS:
Several studies have reported a high accuracy of DUS in comparison with DSA. A recent metaanalysis of studies published between 1996 and 2005 produced a pooled sensitivity of 88% (84--91%) and a pooled specificity of 94% (93--96%) for DUS, confirming data from a former meta-analysis 75--77 (Table 3) . When used by experienced operators and in suitable patients, DUS can produce a map of significant obstructive disease from the abdominal aorta to the feet. DUS can be used for pre-intervention decision-making by predicting whether a patient has anatomy suitable for femoro-popliteal angioplasty with an accuracy of 84--94%. 81, 82 It has also been used as a substitute for DSA for infrainguinal bypass grafting to select the most appropriate tibial vessel for distal anastomosis, although some studies have suggested that DUS alone is inferior to DSA for evaluation of tibial arteries for distal bypass surgery. 83--90 Another study has demonstrated no difference in patency of infrapopliteal bypass grafts in non-randomised cohorts of patients evaluated by pre-operative DUS vs. angiographic methods. 85 DUS can also be used for post-revascularisation surveillance of venous and prosthetic grafts. Venous grafts may fail due to de novo obstructions either within the body of the graft or at the anastomoses (intimal hyperplasia), or due to progression of atherosclerotic obstructions upstream or downstream from the graft. DUS surveillance studies can detect these obstructions during impeding graft thrombosis with greater sensitivity than evaluation by clinical history, physical examination, or use of the resting ABI. 1,91--96 In general, low velocities indicate poor arterial inflow, proximal stenosis, or large graft diameter. One study showed that presence of a PSV less than 45 cm/s within a graft indicates that subsequent graft failure is likely to occur. 97, 98 Another study found that vein grafts that were revised on the basis of positive DUS findings had a 90% 1-year patency rate, similar to grafts with initially normal duplex examinations. Grafts that were not revised despite the presence of a DUSdetected stenosis had a patency rate of only 66% at 1 year. 92 Unfortunately, three RCTs offered conflicting results, with a 3-year primary assisted patency rate of vein grafts monitored with DUS of 78% vs. 53% for those followed up clinically and with the ABI in one study and no improved patency in the others. 99, 100 The Vein Graft Surveillance Randomised Trial (VGST) 101 assessed the benefits of DUS compared with clinical vein graft surveillance in terms of amputation rates, quality of life and healthcare costs in patients after femoropopliteal and femorocrural vein bypass grafts. A total of 594 patients with a patent vein graft at 30 days after surgery were randomised to either a clinical or a duplex follow-up programme at 6 weeks, then 3, 6, 9, 12, and 18 months post-operatively. Both groups had similar amputation rates (7% for each group) and vascular mortality rates (3% vs. 4%) over 18 months. More patients in the clinical group had vein graft stenoses at 18 months (19% vs. 12%, p = 0.04), but primary patency, primary assisted patency and secondary patency rates, respectively, were similar in the clinical group (69%, 76% and 80%) and the duplex group (67%, 76% and 79%). There were no apparent differences in health-related quality of life, but the average health service costs incurred by the DUS surveillance programme were greater by £495 (95% CI £83--807) per patient. The authors concluded that intensive surveillance with DUS did not show any additional benefit in terms of limb salvage rates for patients undergoing vein bypass graft operations, but it did incur additional costs. 101 In a further prospective study, a normal DUS scan 6 weeks subsequent to infrainguinal vein bypass grafting was associated with a 40-month cumulative patency rate of 82%, indicating that further DUS surveillance in these patients is not beneficial. 102 There is an ongoing transatlantic discussion whether or not DUS surveillance is beneficial in patients with infrainguinal venous bypass grafting, with a tendency for routine DUS in these patients in North America, 103--105 while the situation in Europe remains equivocal. 102, 106, 107 DUS surveillance of synthetic grafts is of questionable value. Several studies have found no improvement in patency of grafts, whereas other studies have successfully detected stenoses and found some improvement in patency. This lack of evidence may be due to DUS-associated technical challenges (inability to visualise the stenosis, vascular anatomic challenges) or procedural challenges, such that the subsequent graft revision does not help to improve long-term graft patency.
1,100,101,108--111 DUS surveillance after angioplasty (PTA) procedures is also of questionable value. Immediately after PTA, several studies suggested that velocities in the treated segment may be abnormally elevated and do not predict decreased subsequent patency rates. This may be due to angioplasty-induced vessel dissections that successfully remodel over time. DUS is useful in evaluations for recurrent obstructions. 1,112--119 Although it is reasonable to assume that revisions of post-PTA restenoses that are detected by DUS studies might improve patency, there are no published studies confirming this approach on a high evidence level. 1 
Summary messages: Advantages and disadvantages of duplex ultrasound:
• DUS is non-invasive, relatively inexpensive and as an outpatient procedure well tolerated by patients.
• DUS can also be performed in emergency situations on the ward or in the operating theatre.
• There are limitations to the visualisation of iliac vessels in the pelvis (due to body habitus and bowel gas), very distal arteries and collaterals. In addition, extensive calcification may produce incomplete examinations and in patients in whom multi-level PAD downstream stenoses are detected the sensitivity is decreased, perhaps owing to slow flow. 120, 121 • The technique is highly operator-dependent and proper training is mandatory. 98 • Since the vast majority of DUS studies were performed in mixed populations, the validity of DUS imaging for CLI patients alone is still uncertain.
• No side effects or adverse events have been reported. Recommendations in current guidelines (Table 4) The current ACC/AHA Practice guidelines for PAD patients give a strong recommendation that DUS is useful to diagnose the anatomical location and degree of obstruction of PAD. (Level 1a; Grade A)
Despite the discrepancies mentioned above, DUS surveillance of venous grafts is also recommended with regular follow-up intervals (3, 6, 12 months, and then yearly after graft placement). 1 (Level 2b; Grade B)
The guidelines for non-invasive vascular laboratory testing from the American Society of Echocardiography and the Society for Vascular Medicine and Biology recommend DUS evaluation of the graft twice during the first postoperative year, and annually thereafter. 98 The ACC/AHA guidelines consider DUS also as useful to select patients as candidates for endovascular intervention or surgical bypass (Grade B) and state that DUS may also be considered for routine surveillance after femoropopliteal bypass with a synthetic graft (Level 2b; Grade B).
Finally, DUS is not well established to assess long-term patency of PTA.
1 (Level 2b; Grade B)
Critical issues • The majority of DUS studies are more than 10 years old. New studies should consider following the STARD guidelines for reporting of diagnostic accuracy studies and should also consider reporting results by patient or by limb, as well as by segment.
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• Future reviews should make use of the QUADAS as a quality assessment tool specifically developed for systematic reviews of diagnostic accuracy studies.
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• Further research should consider comparing DUS directly with MRA and/or CTA as the reference standard.
• The value of the operative or endovascular correction of DUS-detected post-PTA lesions has to be evaluated in further studies. • Future studies should identify patients with infrainguinal vein or prosthetic bypasses, who benefit from a standardised DUS surveillance programme.
• The validity of DUS imaging for patients with CLI needs to be evaluated in patient cohorts suffering from rest pain or non-healing ischaemic lesions in the foot.
Computed tomography angiography
Computed tomography angiography (CTA) is increasingly attractive due to rapid technical developments. Shorter acquisition times, thinner slices, higher spatial resolution, and improvement of multidetector computed tomographic (CT) scanners enable scanning of the entire vascular tree in a limited period with a decreasing amount of contrast medium and radiation burden. Accuracy of CTA: In a recent meta-analysis, 20 studies published between 1966 and 2008 (957 patients) were reviewed systematically by use of the QUADAS checklist. 126 Between 167 and 4743 arterial segments were analysed in each study (median 730 segments) and 29% of all segments had stenoses or occlusions. Slice thickness varied between 0.75 and 5.0 mm (median 2.0 mm). Various contrast media were used for the CTA (Iomeprol in 6 studies, iopromide in 4 studies, and the remaining studies used other iodinebased contrast media). The iodine concentration varied between 300 and 400 mg/mL. The amount of contrast volume administered per scan varied between 88 and 170 mL (median 130 mL). Interpretation of CTA was always based on the axial images. Other image reconstructions used were maximum-intensity projections (n = 17), volume-rendering technique (n = 15), multiplanar reformation (n = 6), curvedplanar reformation (n = 4), and virtual endoscopy (n = 1). The pooled sensitivity to detect a >50% stenosis or occlusion was 95% (92--97%) and the pooled specificity 96% (93--97%). CTA correctly identified occlusions in 94% of segments, the presence of >50% stenosis in 87% of segments, and absence of significant stenosis in 96% of segments. Overstaging occurred in 8% of segments and understaging in 15%. The data included trials of CTA vs. DSA across three different generations of CT technology (i.e., scanners with 4, 16, and 64 detector rows) and with technological advancement there has been a corresponding improvement in diagnostic accuracy (sensitivity and specificity has increased from 75--99% and 83--99% with 4 detector rows to 98--99% and 96--99% for 64 detector rows). Diagnostic accuracy was lower for smaller arteries compared with proximal lesions, but the diagnostic performance below the knee remains good (sensitivity 85--99%, specificity 79--97%) ( Table 3) . Inter-observer agreement is good to excellent (k values >0.8) in most studies. 126 The great majority of patients in trials of peripheral arterial Chapter II: Diagnostic Methods S23 Table 5 Recommendations in current guidelines for CT angiography imaging in patients with CLI
Grade of recommendation
Level of evidence CTA of the extremities may be considered to diagnose anatomic location and presence of significant stenosis in patients with lower extremity PAD a .
B 3 a
CTA of the extremities may be considered as a substitute for MRA for those patients with contraindications to MRA a .
Patients with baseline renal insufficiency should receive hydration before undergoing CTA a . A 2 b
CLI, critical limb ischaemia; CTA, computed tomography angiography; MRA, magnetic resonance angiography; PAD, peripheral arterial disease. a Adapted from Hirsch et al. 1 imaging are claudicants and there are limited data in patients with CLI. In a recent study of 28 patients with CLI who were evaluated with 16-detector-row CTA, 23 had treatment plans confidently formulated on the basis of the CTA alone.
Side effects/adverse events: The average radiation dose reported in the CTA literature is 7.47 mSv, 127 although average doses as high as 13.7 mSv have been reported in some series. 128 In a trial of 16-detector-row CTA vs. DSA, Willmann et al. reported a four-fold higher radiation dose for DSA compared with CTA. 129 To place these doses in context, the average annual background radiation exposure is between 2 and 3 mSv. 80 It has been suggested that patient radiation dose issues are of limited concern in patients with advanced PAD, as their life expectancy is significantly less than the latent period of a radiation-induced malignancy. 130 The late effects of radiation exposure are more important in younger patients, however; physicians should be aware of this issue and strive to keep dosing as low as reasonably possible.
Iodinated contrast agents are associated with an increased risk for contrast-induced nephropathy (CIN), defined as an increase in serum creatinine level >25% or >0.5 mg/dL above baseline within 3 days of contrast administration in the absence of other causes. 73, 131 Patients who are considered at highest risk are those with baseline renal insufficiency, especially those with concomitant diabetes mellitus. Other risk factors for CIN include multiple myeloma, proteinuria, concomitant nephrotoxic drug use, hypertension, congestive heart failure, hyperuricaemia, and dehydration. The risk of CIN is dose-dependent and is higher when contrast is administered intra-arterially than when given intravenously. 132 A systematic review revealed an overall risk of CIN in high-risk patients of 16.8%, 132 although the clinical implications for the development of CIN are not fully understood. Only a minority go on to require renal replacement therapy (<1%), but in a retrospective review of over 16,000 inpatients exposed to contrast media, inhospital mortality rates were five-fold higher (34% vs. 7%) among patients who developed CIN, even after adjustment for comorbidity. 133 High-osmolar contrast puts patients with pre-existing renal impairment at twice as high a risk of developing CIN as low-osmolar contrast. 127 However, in a review from 2004 it was concluded that all patients with pre-existing renal insufficiency were at higher risk for CIN, no matter what type of contrast was used. 134 To prevent CIN pre-emptive hydration is recommended, especially for those patients with renal insufficiency. The optimal type, route, volume, and timing of hydration are not well defined. 1 Likewise, given the ability of angiotensin-converting enzyme inhibitors and angiotensin receptor antagonists to induce efferent arteriole vasodilatation, these medications should be withheld the morning of contrast exposure and restarted after monitoring of normal renal function. Administration of antioxidants, such as mannitol, advocated as renoprotective agents, is not supported by evidence.
Further information is provided by the European Society of Urogenital Radiology (http://www.esur.org).
Summary messages: Advantages and disadvantages of computed tomography angiography:
• CTA in comparison to MRA offers better patient acceptance, a higher speed of examination, a better spatial resolution, and the ability to evaluate previously stented arteries. It is mostly applicable in patients with contraindications for MRA (Table 5 ).
• Disadvantages of CTA include image interference from calcified arteries and the need for potentially nephrotoxic contrast agents and radiation exposure.
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Recommendations from other guidelines ( Table 5) :
The current ACC/AHA Practice Guidelines give a moderate recommendation for CTA of the extremities to diagnose anatomic location and presence of significant stenosis in patients with lower extremity PAD. (Level 2B; Grade B)
In addition, CTA of the extremities may be considered as a substitute for MRA for those patients with contraindications to MRA. 
• CTA assessment of aorto-iliac and femoral lesions seems to be sufficient for decision planning, whereas this may not be the case for smaller calcified arteries.
• Specificity is probably overestimated due to the fact that all studies divided the vascular tree into segments with a relatively high proportion of segments without a significant stenosis (segments that are likely to be correctly identified by CTA). From a clinical standpoint, it is more useful to divide the vascular tree into clinically relevant segments (eg, aorto-iliac, femoropopliteal, and distal runoff).
• The statistical power of the available meta-analyses is limited by the relatively small sample size of most included studies. Larger studies are needed.
• New CTA studies should consider to follow the STARD guidelines for reporting of diagnostic accuracy studies and should also consider reporting results by patient or by limb, as well as by segment. 123--125 • Future reviews should make use of the QUADAS as a quality assessment tool specifically developed for systematic reviews of diagnostic accuracy studies. 126 
Magnetic resonance angiography
There have been major technical advances in recent years including 3D contrast enhanced magnetic resonance angiography (ce-MRA) and the development of moving tabletops which enable whole limb examinations with a single contrast injection. Accuracy of MRA: A number of meta-analyses and systematic reviews support the diagnostic accuracy of MRA when compared to DSA. 78, 135, 136 Two meta-analyses determined that 3D ce-MRA is superior to 2D time-of-flight MRA. 123, 137 The meta-analysis by Collins et al. 123 detected a pooled sensitivity of 95% (92--100%) and a pooled specificity of 97% (64--99%) for MRA which was superior to CTA and DUS when compared separately to DSA. There was no direct comparison between MRA and DUS in any of the studies. 78, 123 A well-conducted systematic review concluded that MRA is also cost-effective in comparison to DSA when both are available locally. 137 The most recent metaanalysis included 32 studies published between 1998 and 2009 (120--1780 segments per study, median 384 segments, altogether 1022 patients, 26% with CLI). The pooled sensitivity of MRA was 95% (92--96%) and the specificity was 96% (94--97%) for diagnosing segmental stenosis >50% or occlusions. The accuracy for tibial lesions was slightly worse compared to aorto-iliac and femoropopliteal lesions (Table 3) . MRA correctly classified 95.3%, overstaged 3.1%, and understaged 1.6% of arterial segments. 138 Some studies claim that MRA is superior to DSA in the detection of outflow vessels suitable for distal bypass in patients with CLI. 79, 139 Kreitner et al. found that in 24 diabetic patients with CLI, 38% had pedal vessels detected by MRA that were not detected by catheter angiography. 139 Such vessels treated with surgical bypass may enjoy satisfactory patency. 140 The claim that MRA is more sensitive than DSA for distal vessels is controversial and is affected by the quality of the comparative catheter angiogram. 141 At least one study has shown MRA to be inferior to catheter angiography, particularly for patients with CLI. 142 However, other studies have demonstrated agreement between pre-operative plans based on MRA vs. DSA of at least 90%, and many centres no longer perform DSA before revascularisation.
MRA has been used anecdotally for the assessment of surgical and endovascular revascularisation. Several series of small numbers of patients have shown that the sensitivity and specificity of MRA compared with catheter angiography for detection of stenoses in vein or synthetic bypass grafts is 90--100%. 143--146 For immediate post-procedural evaluation of angioplasty sites, agreement with catheter angiography is 80--95%. 147, 148 There have been no published studies that validate improved patient outcomes from postrevascularisation MRA surveillance.
Side effects/adverse events: Gadolinium-enhanced MRA avoids radiation and gadolinium chelates cause anaphylactic reactions less often than iodinated contrast medium (<1% of all patients). 149 The US Food and Drug Administration has recommended that patients not receive gadolinium-based contrast agents if they have acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min per 1.73 m 2 ) or renal dysfunction due to the hepatorenal syndrome, or are in the peri-operative liver transplantation period, because of the risk for nephrogenic systemic fibrosis (NSF). 150 Apart from other factors, this risk seems to depend on the stability and the dose of the applied gadolinium chelates. However, most patients with PAD do not belong to these risk groups and do not have a specific risk for NSF according to current knowledge.
Summary messages: Advantages and disadvantages of magnetic resonance angiography • MRA, in comparison with DSA and CTA, eliminates exposure to ionising radiation and there is no risk of CIN when gadolinium is used in recommended doses.
• Unlike DUS and CTA, MRA is unaffected by arterial calcification.
• MRA is performed as a fast non-invasive outpatient procedure (<15 minutes).
• Three-dimensional images of the entire arterial tree are presented in a maximum intensity projection format produced on a workstation.
• Relative disadvantages include a tendency to overestimate stenosis. Venous contamination can obscure arteries below the knee. Claustrophobia and the presence of metallic implants (such as pacemakers) or foreign bodies may preclude the examination or produce artefacts.
• MRA tends to overestimate the degree of stenosis because of turbulence and metal clips can cause artefacts that mimic vessel occlusions. Similarly, some metal stents will obscure vascular flow.
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• Patients with pacemakers and defibrillators and some cerebral aneurysm clips cannot be scanned safely.
147,152
Recommendations from other guidelines ( Table 6 ):
The current ACC/AHA Practice Guidelines give a strong recommendation for MRA to diagnose anatomical location and presence of significant stenosis in patients with lower extremity PAD. The ACC/AHA gives moderate recommendations for MRA as a suitable tool to select the sites of surgical anastomosis for surgical bypass and to consider MRA for postrevascularisation (endovascular and surgical bypass) surveillance in patients with lower extremity PAD.
(Level 2b; Grade B)
The Scottish Guideline also gives a strong recommendation that non-invasive imaging modalities should be employed in the first instance for patients with intermittent claudication in whom intervention is being considered. No recommendation is given for patients with CLI. 
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• Specificity is probably overestimated due to the fact that all studies divided the vascular tree into segments with a relatively high proportion of segments without a significant stenosis (segments that are likely to be correctly identified by MRA). From a clinical standpoint, it is more useful to divide the vascular tree into clinically relevant segments (e.g. aorto-iliac, femoropopliteal, and distal runoff).
• New MRA studies should consider to follow the STARD guidelines for reporting of diagnostic accuracy studies and should also consider reporting results by patient or by limb, as well as by segment. 123--125 • Future MRA reviews should make use of the QUADAS as a quality assessment tool specifically developed for systematic reviews of diagnostic accuracy studies. 126 
Intra-arterial angiography
Digital subtraction angiography (DSA) has been the traditional first-line imaging investigation for patients with PAD for many years and, although it is a two-dimensional technique, is still considered the gold standard against which other techniques are compared. Accuracy of DSA: Angiography served as reference tool for new non-invasive diagnostic tools, such as DUS, MRA and CTA. Even though non-invasive modalities are used as first-line diagnostic methods for patients with PAD by many physicians, DSA is still the only universally accepted method for guiding percutaneous peripheral interventional procedures.
Even though DSA is still considered to be the gold standard, there are a number of flaws: 1, 154 • It may not be possible to determine haemodynamic significance even with multiple projections.
• It may overestimate the length of occlusions.
• It may not always demonstrate patent crural vessels.
• Eccentric lesions are sometimes difficult to quantify; axial imaging techniques (e.g., MRA and CTA) may offer an advantage for visualising these pathologies, because these techniques offer a 3D view. Side effects/adverse events: Although it has been estimated that 1.7% of complications may be severe, improvements in catheter and guidewire technology have reduced their incidence significantly. 154, 155 According to the TASC II Consensus, angiography carries an approximately 0.1% risk of severe reaction to contrast medium, a 0.7% risk of complications severe enough to alter patient management, and 0.16% mortality risk and significant expense. 2 Contrast agents are also associated with a small but important incidence of nephrotoxicity. Patients who are at increased risk of contrast nephropathy include those with severe baseline renal dysfunction, diabetes, low cardiac output state, or dehydration. Recent studies have suggested that use of low-osmolar contrast agents (e.g. iodixanol) may reduce the incidence of renal compromise. 156--159 In patients who are high risk for nephrotoxicity, data suggest that vigorous hydration before administration of contrast may serve as the most important strategy to prevent post-procedural deterioration in renal function. Because the occurrence of nephrotoxicity appears to be dosedependent, it is also important to minimise contrast usage. This dose minimisation can be accomplished by using DSA techniques and placing catheters close to the site to be imaged (selective angiography). The dose--nephrotoxicity relationship is complex and cannot be calculated precisely. Preliminary data suggest that nephrotoxicity might be further minimised by use of preprocedural haemofiltration in individuals with chronic renal failure (defined as a creatinine level >2.0 mg/dL). 160 The procedure involves exposure to ionising radiation and short-stay recovery facilities. Other complications include arterial dissection, atheroemboli and access site complications (e.g. pseudoaneurysm, arteriovenous fistula and haematoma). These problems have been greatly mitigated by technological improvements in the procedure, including the use of non-ionic contrast agents, DSA, intra-arterial pressure measurements across a stenosis with and without vasodilator (significance peak systolic difference 5--10 mmHg pre-vasodilatation and 10--15 mmHg post-vasodilatation), and more sophisticated image projection and retention. Alternatively, carbon dioxide and magnetic resonance contrast agents (e.g. gadolinium) can be used instead of conventional contrast media. In high-risk (e.g. renal impairment) patients, restriction to a partial study with selected views rather than visualising the entire infrarenal A history of contrast reaction should be documented before the performance of contrast angiography and appropriate pretreatment administered before contrast is given b . The opportunity to replace DSA with MRA could be considered.
A 2 a
Decisions regarding the potential utility of invasive therapeutic interventions (percutaneous or surgical) in patients with lower extremity PAD should be made with a complete anatomic assessment of the affected arterial territory, including imaging of the occlusive lesion, as well as arterial inflow and outflow with angiography or a combination of angiography and non-invasive vascular techniques b .
A 2 a DSA is recommended for contrast angiographic studies because this technique allows for enhanced imaging capabilities compared with conventional unsubtracted contrast angiography b .
A 2 a
Before performance of contrast angiography, a full history and complete vascular examination should be performed to optimise decisions regarding the access site, as well as to minimise contrast dose and catheter manipulation b .
A 3 b
Selective or superselective catheter placement during lower extremity angiography is indicated because this can enhance imaging, reduce contrast dose, and improve sensitivity and specificity of the procedure b .
A 2 b
The diagnostic lower extremity arteriogram should image the iliac, femoral, and tibial bifurcations in profile without vessel overlap b .
When conducting a diagnostic lower extremity arteriogram in which the significance of an obstructive lesion is ambiguous, transstenotic pressure gradients and supplementary angulated views should be obtained b .
Patients with baseline renal insufficiency should receive hydration before undergoing contrast angiography b .
Follow-up clinical evaluation, including a physical examination and measurement of renal function, is recommended within 2 weeks after contrast angiography to detect the presence of delayed adverse effects, such as atheroembolism, deterioration in renal function, or access site injury (e.g., pseudoaneurysm or arteriovenous fistula) b .
A 3 a
Non-invasive imaging modalities, including MRA, CTA, and colour flow duplex imaging may be used in advance of invasive imaging to develop an individualised diagnostic strategic plan, including assistance in selection of access sites, identification of significant lesions, and determination of the need for invasive evaluation b .
A 2 a CLI, critical limb ischaemia; CTA, computed tomography angiography; DSA, digital subtraction angiography; MRA, magnetic resonance angiography; PAD, peripheral arterial disease. a Adapted from Hessel et al. 154 b Adapted from Hirsch et al. 1 arterial tree has decreased the contrast load, length of study and associated risks. Despite this, full angiography, with visualisation from the level of the renal arteries to the pedal arteries using DSA techniques, remains the choice in most cases.
Summary messages: Advantages and disadvantages of digital subtraction angiography • DSA provides a complete arterial map of the lower limb circulation that is easily interpretable. Images are easily displayed and interpreted by the vast majority of physicians caring for patients with PAD.
• Pressure gradients can be measured to determine haemodynamic significance and it can be used to guide endovascular intervention.
• Disadvantages include complications of catheterisation which may occur both within the vessel and at the puncture site.
Recommendations from other guidelines ( Table 7) :
The current ACC/AHA Practice Guidelines give the following Grade A recommendations:
(1) DSA provides detailed information about arterial anatomy and is recommended for evaluation of patients with lower extremity PAD when revascularisation is contemplated. (Level 2b; Grade B) The ACC/AHA also suggests that non-invasive imaging modalities, including MRA, CTA, and colour flow duplex imaging, may be used in advance of invasive imaging to develop an individualised diagnostic strategic plan, including assistance in selection of access sites, identification of significant lesions, and determination of the need for invasive evaluation. 
